[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351942-105":59,"doc-detail-351942-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","seasonal-variation-in-immune-related-adverse-events-in-advanced-cancer-patients","Seasonal variation in immune-related adverse events in advanced cancer patients","","Immune checkpoint inhibitors improve outcomes in advanced cancers but can trigger immune-related adverse events (irAEs), whose development may vary with environmental seasonality. A retrospective analysis evaluated 709 patients with advanced non-melanoma solid tumors treated at two Australian tertiary centers from 2014–2024. Seasonal patterns were assessed for irAE incidence, organ distribution, severity, and timing, using descriptive analyses, Kaplan–Meier estimates, and Cox models. Winter initiation showed higher overall irAE rates, while summer initiation had higher proportions of grade ≥3 events, alongside regimen-intensity differences.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/seasonal-variation-in-immune-related-adverse-events-in-advanced-cancer-patients/351942/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/seasonal-variation-in-immune-related-adverse-events-in-advanced-cancer-patients/351942.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What patient group and treatments were included in this study?","Question",{"text":112,"@type":113},"The study included 709 patients with advanced non-melanoma solid tumors treated with anti-PD-1/PD-L1 and/or anti-CTLA-4 (monotherapy or in combination) at two Australian tertiary centers between 2014 and 2024.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the season of ICI initiation relate to irAE rates and severity?",{"text":117,"@type":113},"Winter initiation led to the highest overall irAE rate, largely driven by low-grade cutaneous and thyroid events. Summer initiation showed the highest proportion of grade ≥3 irAEs, while winter had the lowest.",{"name":119,"@type":110,"acceptedAnswer":120},"Was season of ICI initiation significantly linked to overall irAE risk?",{"text":121,"@type":113},"No. Season of ICI initiation was not significantly associated with overall irAE risk (p = 0.174) or time to onset (p = 0.11). However, timing to first irAE differed by the season of toxicity onset.",{"name":123,"@type":110,"acceptedAnswer":124},"What did the study suggest about irAE timing?",{"text":125,"@type":113},"Earlier irAEs occurred in spring and summer, indicating that seasonal influences may affect when toxicities emerge, even if the initiation season does not change the overall risk.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},351942,1790339622,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Cancer Immunology, Immunotherapy (2026) 75:180  \n[https://doi.org/10.1007/s00262-026-04423-x](https://doi.org/10.1007/s00262-026-04423-x)  \nSeasonal variation in immune‑related adverse events in advanced cancer patients  \nRoger Liang1,2,3 · Bo Gao2,3,4 · Adnan Nagrial2,3,4 · Tania Moujaber2,3,4 · Matteo S. Carlino2,3,4,5 · Pei N. Ding2,4 · Howard Gurney2 · Mark Wong2 · Rosemary Habib2,3 · Serigne N. Lo1,5,6 · Janet McKeown5 · Ines Pires da Silva5,7  \nReceived: 20 March 2026 / Accepted: 8 May 2026 © The Author(s) 2026  \nAbstract  \nBackground Immune checkpoint inhibitors (ICIs) improve outcomes across advanced cancers but can cause immune-related adverse events (irAEs). Seasonal environmental factors influence immune regulation and autoimmunity, yet its relationship with irAE development in non-melanoma cancers remains poorly defined.  \nMethods We retrospectively analysed patients with advanced non-melanoma solid tumours treated with anti-PD-1/PD-L1 and/or anti-CTLA-4 monotherapy at two Australian tertiary centers between 2014–2024. Seasonal variation in irAE incidence, organ distribution, severity, and timing were evaluated using descriptive analyses, Kaplan–Meier estimates and Cox proportional hazards models.  \nResults Among 709 patients across 27 cancer types (median follow-up 12.7 months), 514 irAEs occurred, including 32% grade ≥ 3 events and 14% treatment discontinuation rate due to toxicity. Winter ICI initiation led to the highest irAE rate (0.89 events per treatment) versus summer (0.62), largely driven by seasonal variation in low-grade cutaneous and thyroid events. Summer ICI initiation showed the highest proportion of grade ≥ 3 irAEs, whereas winter had the lowest. Seasonal effects also differed by regimen intensity, with disproportionately more irAEs among patients commencing doublet ICIs in winter. Season of ICI initiation was not significantly associated with overall irAE risk (p = 0.174) or time to onset (p = 0.11) . However, time to first irAE differed by season of toxicity onset (p = 0.019), with earlier irAEs occurring in spring and summer. Conclusions Although there was no significant association between season of ICI initiation and overall irAE risk, we observed seasonal variations in the phenotype, severity, and timing of irAEs. These exploratory findings may inform future investigation into seasonal influences on immune toxicity.  \nKeywords Seasonal · Immunotherapy · Immune checkpoint inhibitors · Immune-related adverse events · Toxicity · Advanced cancer  \n* Roger Liang[rlia8791@uni.sydney.edu.au](rlia8791@uni.sydney.edu.au)  \n1 Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, NSW 2050, Australia  \n2 Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia  \n3 Blacktown Cancer & Haematology Centre, Blacktown Hospital, Sydney, NSW, Australia  \n4 Westmead Clinical School, The University of Sydney, Sydney, NSW, Australia  \n5 Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia  \n6 Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia  \n7 Champalimaud Foundation, Lisbon, Portugal  \nIntroduction  \nImmune checkpoint inhibitors (ICIs) are an important pillar of the anticancer armamentarium for many advanced cancers, resulting in improved survival rates for patients across multiple solid tumour types [1–6] . As ICIs induce antitumour immune responses, there is a risk of generating an undesirable immune response against normal tissues. This can potentially lead to an idiosyncratic class of side effects known as immune-related adverse events (irAEs), which can affect any organ and ranges in severity from mild to life-threatening [7] . Although most irAEs are typically reversible, they can significantly impact patient quality of life from treatment interruptions, invasive diagnostic  \nprocedures, hospitalisations, and, in rare cases, permanent organ dysfunction or even death [8–10] .  \nKnown risk factors for developing irAE","cbCaibPR5f2TEObB","https://ap.wps.com/l/cbCaibPR5f2TEObB","pdf",1310486,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Methods\n## Study design and population","[{\"question\":\"What patient group and treatments were included in this study?\",\"answer\":\"The study included 709 patients with advanced non-melanoma solid tumors treated with anti-PD-1/PD-L1 and/or anti-CTLA-4 (monotherapy or in combination) at two Australian tertiary centers between 2014 and 2024.\"},{\"question\":\"How did the season of ICI initiation relate to irAE rates and severity?\",\"answer\":\"Winter initiation led to the highest overall irAE rate, largely driven by low-grade cutaneous and thyroid events. Summer initiation showed the highest proportion of grade ≥3 irAEs, while winter had the lowest.\"},{\"question\":\"Was season of ICI initiation significantly linked to overall irAE risk?\",\"answer\":\"No. Season of ICI initiation was not significantly associated with overall irAE risk (p = 0.174) or time to onset (p = 0.11). However, timing to first irAE differed by the season of toxicity onset.\"},{\"question\":\"What did the study suggest about irAE timing?\",\"answer\":\"Earlier irAEs occurred in spring and summer, indicating that seasonal influences may affect when toxicities emerge, even if the initiation season does not change the overall risk.\"}]","Seasonal variation in immune-related adverse events in advanced cancer patients | PDF",1790096556,35,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/29bc4af5b96bf4bbb0bdc4e05f3edcf2.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f83deba2a9b19eacdc6633c2b967bb07.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/114a0d202e489053edcd5e87809c82a0.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5bb0793e8515bc41d6e6648df6033a3.webp",980,1301]